Clinical Trial

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The aim of this study is to identify the optimal dose for EP0062 as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-10-05; most recent amendment 2026-06-17.
Status change: Not Yet Recruiting → Recruiting 2023-06-09
Trial Details
NCT Number NCT05573126
Lead Sponsor Ellipses Pharma
Conditions Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
Enrollment 95 participants
Start Date 2023-01-11
Primary Completion 2028-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-06-22